Galinpepimut-S, a peptide vaccine for acute myeloid leukemia, met the main goal of its phase 3 trial. People given it lived a median of 24.0 months, while people on standard treatment lived 14.7 months.1
The result is narrower than the headline number suggests. It rests on 80 deaths among 126 patients. Its p-value of 0.035 sits close to the usual cutoff of 0.05. SELLAS Life Sciences, the company developing it, announced it on November 17, 2026 without a confidence interval, death counts for each arm or the full data.1 Nothing has been peer reviewed yet.
What did the REGAL trial find?
People given galinpepimut-S, known as GPS, had a 41% lower risk of death than people on the best available treatment in the REGAL trial, a hazard ratio of 0.59.1
| REGAL result | Galinpepimut-S | Best available treatment |
|---|---|---|
| Median overall survival | 24.0 months | 14.7 months |
| Hazard ratio for death | 0.59 | |
| Two-sided p-value | 0.035 | |
| Patients randomized, in total | 126 | |
| Deaths at the final analysis | 80 | |
| Confidence interval | Not released |
Overall survival was the trial's primary endpoint, and the final analysis ran when the 80th death occurred, as the plan specified.1 The median gap is 9.3 months.
On safety, SELLAS reports that most treatment-related side effects were mild to moderate and were mostly reactions at the injection site, with no new safety signals.1 The company has not published the safety tables behind that summary.
Who was in the trial?
Adults with acute myeloid leukemia, or AML, qualified for the trial if they had reached a second or later remission after further rounds of treatment. They also had to be unable to have a stem cell transplant.1 For people with AML, a transplant is often the main route to long-term control, so this group has few options left. The trial's steering committee, chaired by Hagop Kantarjian of MD Anderson, said such patients "face poor survival outcomes".2
Patients were randomized one to one. Half got GPS on its own. The other half got their doctor's choice of best available treatment: observation alone, a hypomethylating agent, venetoclax or low-dose cytarabine.1 The trial was open-label, so patients and doctors knew which treatment each person received.1
What is galinpepimut-S?
Galinpepimut-S is a vaccine made of four peptides taken from WT1, a protein found in many leukemias and solid tumors.1 It is meant to train both CD4 and CD8 T cells, two arms of the immune system, to recognize cancer cells that carry WT1. SELLAS is testing it as maintenance therapy, given during remission to keep the leukemia from returning.1 Despite the word vaccine, it is not meant to prevent leukemia in healthy people. It is given to patients who already have the disease and are in remission. The company licensed it from Memorial Sloan Kettering Cancer Center, where it was discovered in the laboratory of David Scheinberg.1
Most peptides people hear about online are sold for recovery or fat loss. GPS belongs to a different line of work, the peptide cancer vaccines. Our pages on nelipepimut-S and rindopepimut cover two that reached late-stage trials and failed. The RYZ101 phase 3 result and the KRAS pancreatic vaccine are the other recent peptide cancer stories on this site.
How strong is the result?
The result is statistically significant by the usual standard, though only just. A two-sided p-value of 0.035 is below the conventional 0.05 line, and with only 80 deaths behind it, the estimate is fragile.1
SELLAS released no confidence interval. An approximate one can be worked back from the hazard ratio and p-value it did release, using a standard method. That arithmetic gives a 95% interval of about 0.36 to 0.96. The figure is this page's calculation, not the company's, and Tech Times reached the same range independently.3 An upper end that close to 1.0 means the data fit anything from a large benefit to a small one.
Being open-label matters less here than it would for a symptom score, because death is not a matter of judgment. It can still affect care along the way. Doctors who know a patient is on standard care may treat a relapse differently, and the release does not say what later treatments either group received.
Why did the trial take so long, and why did its targets change?
REGAL took far longer than planned because patients in the trial lived longer than expected. In November 2022, SELLAS reported that blinded, pooled data from both arms suggested median survival was "approximately two-fold" longer than the trial had assumed.4 The company changed the plan in response.
| Change announced November 14, 2022 | Before | After |
|---|---|---|
| Deaths needed for the final analysis | 105 | 80 |
| Deaths needed for the interim analysis | 80 | 60 |
| Patients to enroll | 116 | 125 to 140 |
SELLAS's revised plan said statistical significance would come with a hazard ratio of 0.636, "corresponding to an OS of 12.6 months versus eight months for GPS versus BAT".4 Both arms beat those figures by a wide margin. At 14.7 months, the control arm lived about 84% longer than the eight months the plan used, and the November 2026 release does not say why.1
An interim analysis came at 60 deaths. In January 2025 the trial's independent monitoring committee found that GPS had passed its futility test and recommended continuing without changes. The final analysis was then expected later that year.5 SELLAS had earlier forecast the final analysis by the end of 2024.4 It arrived in November 2026.
Cutting the deaths needed for the final analysis shortens a trial. It also gives the statistics less to work with, so the missing confidence interval matters more.
What happens next for galinpepimut-S?
The next step for galinpepimut-S is a meeting with the FDA "to discuss an accelerated filing strategy", followed by a Biologics License Application in the first half of 2027.1 That application is the formal request for FDA approval of a biologic product, and filing it starts a review that can take months. It says the full results, including secondary endpoints, will be presented at an upcoming medical conference and submitted to a peer-reviewed journal.1
Galinpepimut-S is not approved anywhere. Until the full data appear, the questions above stay open: the confidence interval, the deaths in each arm, the shape of the survival curves and the treatments patients received after relapse.
Who has a stake in the result?
SELLAS has the largest stake in the result: it sponsored the trial and holds the license to the vaccine. Its release discloses that Memorial Sloan Kettering has institutional financial interests related to SELLAS, and that David Scheinberg and Javier Pinilla-Ibarz have financial interests of their own.1
Every figure on this page comes from the company or from coverage of its announcement. The independent check, a peer-reviewed paper, has not appeared yet.
Common questions
Did galinpepimut-S pass its phase 3 trial?
Yes, galinpepimut-S met the primary endpoint of the phase 3 REGAL trial, overall survival, according to SELLAS's November 17, 2026 announcement. Median survival was 24.0 months on the vaccine and 14.7 months on standard treatment.
What is galinpepimut-S?
Galinpepimut-S is an investigational cancer vaccine made of four peptides from the WT1 protein, developed by SELLAS Life Sciences. It is designed to train T cells to attack leukemia cells that carry WT1.
Is galinpepimut-S a leukemia vaccine?
Yes, galinpepimut-S is an investigational peptide vaccine for acute myeloid leukemia, developed by SELLAS Life Sciences. It is a treatment for people who already have the disease and are in remission, not a shot that prevents leukemia.
What disease does galinpepimut-S treat?
Galinpepimut-S was tested in the phase 3 REGAL trial in acute myeloid leukemia, in adults in second or later remission who could not have a stem cell transplant.
How much longer did people live on galinpepimut-S?
People on galinpepimut-S lived a median of 24.0 months and people on standard treatment 14.7 months in the REGAL trial, a gap of 9.3 months. The hazard ratio for death was 0.59.
Is the galinpepimut-S result statistically significant?
Yes, the two-sided p-value was 0.035, below the usual 0.05 threshold. SELLAS released no confidence interval, and an approximate one back-calculated from its figures runs from about 0.36 to 0.96.
How many patients were in the REGAL trial?
REGAL randomized 126 patients. Its final analysis came at the 80th death.
Was the REGAL trial blinded?
No, REGAL was open-label, so patients and doctors in the 126-person trial knew who received galinpepimut-S and who received standard treatment.
What did the control group get in REGAL?
Patients in the REGAL control group got their doctor's choice of best available treatment, according to SELLAS's November 2026 release: observation, a hypomethylating agent, venetoclax or low-dose cytarabine.
Why did SELLAS change the REGAL trial plan?
SELLAS reported in November 2022 that pooled survival was about twice as long as the trial had assumed. It cut the deaths needed for the final analysis from 105 to 80 and raised enrollment to 125 to 140 patients.
Is galinpepimut-S FDA approved?
No, galinpepimut-S was not approved anywhere as of November 2026. SELLAS plans to submit a Biologics License Application in the first half of 2027.
When will galinpepimut-S be available?
No date exists, because SELLAS had not filed for approval as of November 2026. It plans to meet the FDA and submit its application in the first half of 2027.
What are the side effects of galinpepimut-S?
SELLAS reported in November 2026 that treatment-related side effects in REGAL were mostly mild to moderate, most commonly injection site reactions, with no new safety signals. Full safety tables have not been published.
Is galinpepimut-S a peptide?
Yes, galinpepimut-S is made of four peptides derived from the WT1 protein. That places it among the peptide cancer vaccines.
What is the WT1 protein?
WT1 is a protein found in many blood cancers and solid tumors, including acute myeloid leukemia. Galinpepimut-S targets it to direct the immune system at cancer cells.
Have other peptide cancer vaccines worked?
Several peptide cancer vaccines have failed in phase 3 trials, including nelipepimut-S in breast cancer and rindopepimut in brain cancer. That makes a positive phase 3 result for galinpepimut-S unusual.
Has the REGAL trial been published?
Not as of November 18, 2026. SELLAS says the full results will go to a medical conference and a peer-reviewed journal.
Sources
- SELLAS Life Sciences. SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia. GlobeNewswire, November 17, 2026. https://ca.finance.yahoo.com/news/sellas-life-sciences-announces-positive-120000814.html.
- Targeted Oncology. Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML. November 18, 2026. https://www.targetedonc.com/view/galinpepimut-s-regal-phase-3-overall-survival-aml.Read via a reproduction: trade press coverage of the announcement, cited only for the steering committee's statement. ↩1
- Tech Times. SELLAS Leukemia Vaccine Cuts Death Risk 41% in Phase 3, but No Confidence Interval Released. November 17, 2026. https://www.techtimes.com/articles/330907/20261117/sellas-leukemia-vaccine-cuts-death-risk-41-phase-3-no-confidence-interval-released.htm.Read at source. Cited only as an independent cross-check of the back-calculated interval. This page computed the interval itself from the released hazard ratio and p-value. ↩1
- SELLAS Life Sciences. SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset Galinpepimut-S in Acute Myeloid Leukemia. November 14, 2022. https://ir.sellaslifesciences.com/news/News-Details/2022/SELLAS-Life-Sciences-Announces-Update-on-Phase-3-REGAL-Clinical-Trial-Evaluating-Lead-Asset-Galinpepimut-S-in-Acute-Myeloid-Leukemia/default.aspx.
- Targeted Oncology. Phase 3 REGAL Trial of Galinpepimut-S in AML Advances Toward Completion. January 24, 2025. https://www.targetedonc.com/view/phase-3-regal-trial-of-galinpepimut-s-in-aml-advances-toward-completion.Read via a reproduction: trade press coverage of SELLAS's interim analysis announcement. This page did not read that announcement directly. ↩1
Citing this page: Peptide Decoding. Galinpepimut-S Won Phase 3 in Leukemia. The Margin Is Thin. Figures from SELLAS Life Sciences' November 17, 2026 and November 14, 2022 releases, with Targeted Oncology's coverage of the interim and final analyses. Reviewed November 18, 2026. https://peptidedecoding.com/news/galinpepimut-s-regal-phase-3

